Veracyte, Inc.

Significant items subject to such estimates include: revenue recognition; the useful lives of property, plant and equipment; the recoverability of long-lived assets; the incremental borrowing rates for leases; the estimation of the fair value of intangible assets and contingent consideration; stock-based compensation; income tax uncertainties, including a valuation allowance for deferred tax assets; credit related losses on investments; and allowance for credit losses and contingencies.

SEC original ↗Veracyte, Inc. — 10-Q Quarterly report10-QJul 31, 2026

The Company classifies these investments as held-to-maturity debt securities, which are reported at amortized cost.

SEC original ↗Veracyte, Inc. — 10-Q Quarterly report10-QJul 31, 2026

In addition, proceeds from exercises of equity awards and the average amount of unrecognized compensation expense for equity awards are assumed to be used to repurchase shares.

SEC original ↗Veracyte, Inc. — 10-Q Quarterly report10-QJul 31, 2026

The estimation of the fair value of the contingent consideration is based on the present value of the expected payments calculated by assessing the likelihood of when the related milestones would be achieved and estimating the Company's borrowing rate.

SEC original ↗Veracyte, Inc. — 10-Q Quarterly report10-QJul 31, 2026

Changes to the forecasts for the achievement of the milestones and the borrowing rate can significantly affect the estimated fair value of the contingent consideration.

SEC original ↗Veracyte, Inc. — 10-Q Quarterly report10-QJul 31, 2026

We believe we are approaching an inflection point with the upcoming launches of Prosigna LDT and TrueMRD, two of the most significant new products in our history, creating meaningful opportunities for market expansion in Breast, Bladder and other cancers, alongside continued growth in our Prostate and Thyroid businesses.

SEC original ↗Veracyte, Inc. — Earnings release (8-K exhibit)EX-99May 5, 2026

Forward-looking statements can be identified by words such as appears, anticipate, intend, plan, expect, believe, should, may, could, would, will, enable, positioned, offers, designed, ultimately, strategic, outlook, guidance, and similar references to future periods.

SEC original ↗Veracyte, Inc. — Earnings release (8-K exhibit)EX-99May 5, 2026

For the three months ended March 31, 2026, adjustments consist primarily of expenses related to the assessment of licensing and strategic investments ($1.7 million) and expenses related to legal proceedings ($0.6 million), partially offset by the impact of Non-GAAP adjustments on IT Facilities allocations ($0.3 million).

SEC original ↗Veracyte, Inc. — Earnings release (8-K exhibit)EX-99May 5, 2026

For the three months ended March 31, 2026, adjustments primarily include impacts from the restructuring and liquidation proceedings of Veracyte SAS ($4.2 million), partially offset by expenses related to the assessment of licensing and strategic investments ($1.7 million), other legal proceedings ($0.6 million) and losses related to asset disposition ($0.4 million).

SEC original ↗Veracyte, Inc. — Earnings release (8-K exhibit)EX-99May 5, 2026

All statements contained in this report other than statements of historical fact, including statements concerning our business strategy and plans, future operating results and financial position, as well as our objectives and expectations for our future operations, are forward-looking statements.

SEC original ↗Veracyte, Inc. — 10-Q Quarterly report10-QJul 31, 2026

For the three months ended March 31, 2026, adjustments consist primarily of expenses related to the assessment of licensing and strategic investments ($1.7 million) and expenses related to legal proceedings ($0.6 million), partially offset by the impact of Non-GAAP adjustments on IT Facilities allocations ($0.3 million).

SEC original ↗Veracyte, Inc. — Earnings release (8-K exhibit)EX-99May 5, 2026

For the three months ended March 31, 2026, adjustments primarily include impacts from the restructuring and liquidation proceedings of Veracyte SAS ($4.2 million), partially offset by expenses related to the assessment of licensing and strategic investments ($1.7 million), other legal proceedings ($0.6 million) and losses related to asset disposition ($0.4 million).

SEC original ↗Veracyte, Inc. — Earnings release (8-K exhibit)EX-99May 5, 2026

Legal Proceedings 31 Item 1A.

SEC original ↗Veracyte, Inc. — 10-Q Quarterly report10-QJul 31, 2026

In some cases, you can identify forward-looking statements by such terminology as believe, may, will, potentially, estimate, continue, ongoing, anticipate, intend, could, would, project, plan, expect or the negative of these terms or similar expressions that convey uncertainty of future events or outcomes, although not all forward-looking statements contain these words.

SEC original ↗Veracyte, Inc. — 10-Q Quarterly report10-QJul 31, 2026

These forward-looking statements speak only as of the date of this report and are subject to a number of risks, uncertainties and assumptions described in the section titled Risk Factors in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025 and elsewhere in this report.

SEC original ↗Veracyte, Inc. — 10-Q Quarterly report10-QJul 31, 2026

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events.

SEC original ↗Veracyte, Inc. — 10-Q Quarterly report10-QJul 31, 2026